116
Participants
Start Date
September 19, 2005
Primary Completion Date
October 19, 2007
Study Completion Date
March 17, 2011
Vicriviroc 30 mg
Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period).
Vicriviroc 20 mg
Two tablets of vicriviroc 10 mg once daily for 48 weeks.
Placebo
Three tablets of placebo once daily for 48 weeks.
Placebo
Two tablets of placebo once daily for 48 weeks.
Background ART Regimen
"An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir."
Merck Sharp & Dohme LLC
INDUSTRY